Recent News

• 03.04.2025 - Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
• 03.04.2025 - Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
• 01.14.2025 - Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
• 01.14.2025 - Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
• 11.25.2024 - Reni Benjamin
• 11.25.2024 - Reni Benjamin
• 11.13.2024 - Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
• 11.13.2024 - Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Recent Filings

• 02.13.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.14.2025 - EX-99.1 EX-99.1
• 01.14.2025 - 8-K Current report
• 12.23.2024 - 8-K Current report
• 11.21.2024 - EFFECT Notice of Effectiveness
• 11.19.2024 - UPLOAD SEC-generated letter
• 11.19.2024 - CORRESP Correspondence
• 11.14.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.13.2024 - EX-99.1 EX-99.1